Proteomics International Laboratories (ASX:PIQ) said it has published study results showing its PromarkerEso blood test can diagnose Esophageal adenocarcinoma (EAC), the predominant form of esophageal cancer, with high accuracy, according to a Thursday filing with the Australian bourse.
The test showed accurately detected EAC, with over 91% sensitivity and about 99% specificity in a 147-person validation study, the filing said.
Shares of the company rose past 1% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.